This site is intended for healthcare professionals

Merck Inc. to acquire Pandion Therapeutics including PT 101 for the potential treatment of ulcerative colitis and other autoimmune diseases.

Read time: 1 mins
Last updated:26th Feb 2021
Published:26th Feb 2021
Type: industry
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest